October 24, 2020

The Niche

Knoepfler lab stem cell blog

CRISPR

2 min read

Here in the U.S. we just had our big Thanksgiving holiday, but science goes, stem cells keep growing and needing attention, and it’s another weekend chance to catch up on our paper reading. Here’s this weekend edition of recommended reads including news items and pubs. From Cell Stem Cell: Single-Cell Transcriptome Analysis of Uniparental Embryos Reveals Parent-of-Origin Effects on Human Preimplantation Development. and another there on stem cell machinery in cancer: Humanized Stem Cell Models of Pediatric Medulloblastoma Reveal an Oct4/mTOR Axis that Promotes Malignancy. …Read More

6 min read

By Guillaume Levrier Human germline editing has been done before. It will be done again in the future, as it is relatively easy to perform. No mechanism with the de facto ability to prevent it from being organized has yet been designed, let alone implemented. But the fact that germline editing has, can, and will happen again does not deprive anyone of their right to have an opinion on this capacity. The CRISPR Consensus symposium (see video below) set up at the Innovative Genomics Institutes …Read More

3 min read

Every so often I realize I’ve accumulated a bunch of tabs on my browsers of things I need to dive into as time permits, which sometimes translates into a collection of recommended reads here on The Niche. Here are some recommended recent reads in the stem cell/regenerative medicine field and childhood cancer space. It includes some great science and complex social and policy developments and opinions. ‘I just want to live’: California man pleads with scientists around the world to ‘CRISPR me’. Remarkably this …Read More

8 min read

ViaCyte is one of the most exciting stem cell and regenerative medicine biotech companies so I like to try to check in with them regularly. Today’s post is my new interview with ViaCyte leader Paul Laikind on recent developments. We had a great chat about the science and how things are looking upbeat for the company, which is growing (a heads up for stem cell biologists who may be job hunting). You can read my previous interview with them from about a year ago …Read More